Takeda setting up independent presence in South Korea
This article was originally published in Scrip
Takeda is to establish a new commercial subsidiary in South Korea as part of a push to build up its direct business presence in what it sees as one of the key markets of the Asian region.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.